Abramson Cancer Center of the University of Pennsylvania ( Site 0309) — Philadelphia, Pennsylvania

Abramson Cancer Center of the University of Pennsylvania ( Site 0309) is a clinical research site located in Philadelphia, Pennsylvania, United States 19104.

Crixeo Health Trust Score: 48/100 (POOR). This profile has not yet been claimed by the site owner.

Abramson Cancer Center of the University of Pennsylvania ( Site 0309) has participated in 1 clinical trials.

Therapeutic areas: Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia.

Sponsors: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

Sponsor Feasibility Report

Trust Score: 48/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Abramson Cancer Center of the University of Pennsylvania ( Site 0309)?

Abramson Cancer Center of the University of Pennsylvania ( Site 0309) has a Crixeo Trust Score of 48/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Abramson Cancer Center of the University of Pennsylvania ( Site 0309) conducted?

Abramson Cancer Center of the University of Pennsylvania ( Site 0309) has 1 clinical trials on record. Their work covers Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia.

Is Abramson Cancer Center of the University of Pennsylvania ( Site 0309) accredited by Crixeo Health?

Abramson Cancer Center of the University of Pennsylvania ( Site 0309) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Abramson Cancer Center of the University of Pennsylvania ( Site 0309)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.